Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial.
Lancet Haematol. 2022 May 9:S2352-3026(22)00103-X. doi: 10.1016/S2352-3026(22)00103-X. Online ahead of print.
Lancet Haematol. 2022.
PMID: 35550060